Clinical trials: Healthy Young Volunteers
Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers
A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers
This study consists of two parts, ie, single dose part with young healthy subjects (Part 1) and single and multiple dose part with elderly healthy subjects (Part 2), to assess the safety, tolerability, pharmacokinetics and…
- Trial name
- NCT02005211
- Testing
- AZD3293
- Where
- Japan
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Epstein Barr Virus (EBV) Infection
Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults
Phase 1, single-center, randomized, placebo-controlled, double-blind clinical trial. Participants (N = 15) will receive a 2-dose schedule (1 vaccination on day 1 and day 28) randomized, receiving either MVA-BN-EBV (n = 12) or…
- Trial name
- NCT07888088
- Testing
- MVA-BN-EBV
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Biomedical Enhancement
The Effects of a Combination of Nootropic Ingredients on Cognition in Healthy Young Volunteers
Achieving optimal concentration during cognitively demanding tasks is of immense human value. Despite our understanding of the important role that attention, working memory, and fluid intelligence play in professional success…
- Trial name
- NCT02857829
- Testing
- CAF+, Caffeine-alone
- Where
- Netherlands
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Nootrobox, Inc.
Alzheimer's Disease
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01978327
- Testing
- GSK2647544, drug-drug interaction
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers
The purpose this study is to evaluate the safety and toleration of PF-03049423 following multiple dose administration as an oral solution to healthy young adult volunteers and healthy elderly volunteers.
- Trial name
- NCT01161069
- Testing
- PF-03049423
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer
Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years., Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80
To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers
AZD2516 is being developed for the oral treatment of chronic neuropathic pain. This study is split in to two parts. Part A will measure the effect of food and a new formulation of the drug in the blood and see how well it is…
- Trial name
- NCT01148095
- Testing
- AZD2516
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Safety and Pharmacokinetic
Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers
This is a single center, randomised, double blind, placebo controlled clinical study to assess the safety and tolerability of MBF-015 in healthy volunteers.This clinical phase I trial is divided in two stages and involves, first…
- Trial name
- NCT06049147
- Testing
- MBF-015 4 mg oral capsule, MBF-015 16 mg oral capsule
- Where
- Spain
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Medibiofarma S.L.
Normal, Healthy Volunteers
A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020
To investigate whether there is a food-effect with oral administration with EB-1020 as well as to obtain information on the safety, and tolerability of EB-1020 in a range of doses.
- Trial name
- NCT01744808
- Testing
- EB-1020 IR, EB-1020 SR1, EB-1020 SR2
- Where
- Australia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy
Study to Assess Safety, Tolerability and Pharmacokinetics After Single and Multiple Doses of AZD1446 to Japanese Subject
The primary aim of this study is to assess the safety and tolerability of AZD1446 following single and multiple ascending doses of an orally administered solution of AZD1446 in healthy young and elderly Japanese subjects.
- Trial name
- NCT01021189
- Testing
- AZD1446
- Where
- Japan
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Safety, Tolerability & PK of AZD0328 in Caucasian & Japanese
This study will be performed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of AZD0328 when administered to Japanese and Caucasian healthy male volunteers.
- Trial name
- NCT00738959
- Testing
- AZD0328
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Contraception
A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles
Investigation of a new pill containing an estrogen and a progestin in order to monitor the inhibition of the ovulation in young healthy females over 3 treatment cycles
- Trial name
- NCT00631124
- Testing
- BAY86-4891 (Estradiol / Drospirenone)
- Where
- 2 sites in Germany
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Bayer
Trigeminal Neuralgia
PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers
A randomized, double-blind, placebo controlled, two period crossover study to investigate the pharmacokinetics, tolerability and cognitive effects of 8 days dosing of CNV1014802 in healthy young versus elderly male and female…
- Trial name
- NCT02359344
- Testing
- CNV1014802
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy Volunteers
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects
Berlin Cures develops BC 007 to treat patients suffering from diseases (chronic heart failure, pulmonary hypertension, chronic fatigue syndrome etc.) which are associated with functional autoantibodies (AAB) directed against…
- Trial name
- NCT02955420
- Testing
- BC 007, NaCl 0.9 %
- Where
- Germany
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Berlin Cures GmbH
Healthy
Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers
The objective of the present study is to obtain information about the safety and tolerability of BIIX 1 XX, to determine the pharmacologically active dose (range) by performing a methacholine challenge test and to obtain…
- Trial name
- NCT02199873
- Testing
- BIIX 1 XX - single rising dose
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Relative Bioavailability of Colcrys™ 0.6 mg Tablets in Healthy Young and Elderly Volunteers Under Fasted Conditions
The purpose of this study is to evaluate and compare the relative bioavailability of a single dose of Colcrys™ (colchicine) 0.6 mg when administered to a group of young , healthy subjects 18-30 years of age compared to a group of…
- Trial name
- NCT01001052
- Testing
- Colcrys™ (colchicine)
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Alzheimer's Disease
Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147
This Phase I clinical study is a randomized, double-blind, placebo-controlled, parallel-design study to thoroughly assess the safety profile and PK properties of J147 in healthy subjects.
- Trial name
- NCT03838185
- Testing
- J147
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Abrexa Pharmaceuticals, Inc.
Tetanus Immunisation (Healthy Volunteers), Diphtheria Immunisation (Healthy Volunteers)
A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada
The primary objectives of this study are: To describe the safety profile of each of the investigational vaccine formulations for all participants To describe the humoral and cell-mediated immune responses to all of the…
- Conditions
- Tetanus Immunisation (Healthy Volunteers), Diphtheria Immunisation (Healthy Volunteers), Pertussis Immunisation (Healthy Volunteers)
- Trial name
- NCT03958799
- Testing
- Investigational Tdap vaccine Formulation B, Investigational Tdap vaccine Formulation C, Investigational Tdap vaccine Formulation A
- Where
- 5 sites in Canada
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Volunteers
Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers
The study is carried out in order to investigate safety, tolerability and pharmacokinetics after administrating single and fractionated doses of AZD3241 to healthy volunteers
- Trial name
- SAD (NCT00729443)
- Testing
- AZD3241
- Where
- Sweden
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Healthy
Study to Determine the Ability of Seresis to Act as a Skin Protection Agent in Healthy Young Female Volunteers
Study to detect the efficacy of Seresis® in reducing the damage produced on the skin by Matrix-metalloproteinases (MMP) and by oxidative stress (marker: heme oxygenase-1 expression) activated by UV radiation
- Trial name
- NCT02191813
- Testing
- Seresis®
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim